Back to Newsroom
Back to Newsroom

LAWSUITS FILED AGAINST WM, OM and TGTX - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

Wednesday, August 3, 2022 9:45 AM
Jakubowitz Law
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / August 3, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Waste Management, Inc. (NYSE:WM)

CONTACT JAKUBOWITZ ABOUT WM:
https://claimyourloss.com/securities/waste-management-inc-loss-submission-form/?id=30529&from=1

This lawsuit is on behalf of all purchasers of certain Waste Management redeemable senior notes between February 13, 2020 and June 23, 2020.

Lead Plaintiff Deadline : August 8, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the U.S. Department of Justice had indicated to Waste Management that it would require Waste Management to divest significantly more assets than the $200 million indicated in the merger agreement between the Company and Advanced Disposal Services; (ii) as a result, the merger would not be completed by July 14, 2020, the end date under the merger agreement; and (iii) the Waste Management redeemable senior notes would be subject to mandatory redemption at 101% of par.

Outset Medical, Inc. (NASDAQ:OM)

CONTACT JAKUBOWITZ ABOUT OM:
https://claimyourloss.com/securities/outset-medical-loss-submission-form/?id=30529&from=1

This lawsuit is on behalf of all persons or entities who purchased Outset Medical common stock between September 15, 2020, and June 13, 2022.

Lead Plaintiff Deadline : September 6, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's flagship product, Tablo Hemodialysis System ("Tablo"), would require an additional 510(k) application to be filed with The United States Food and Drug Administration ("FDA"), as defendants had "continuously made improvements and updates to Tablo over time since its original clearance"; (2) as a result, the Company could not conduct a human factors study on a cleared device in accordance with FDA protocols; (3) the Company's inability to conduct the human factors study subjected the Company to the likelihood of the FDA imposing a "shipment hold" and marketing suspension, leaving the Company unable to sell Tablo for home use; and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and /or lacked a reasonable basis at all relevant times.

TG Therapeutics, Inc. (NASDAQ:TGTX)

CONTACT JAKUBOWITZ ABOUT TGTX:
https://claimyourloss.com/securities/tg-therapeutics-inc-loss-submission-form/?id=30529&from=1

Class Period : January 15, 2020 - May 31, 2022

Lead Plaintiff Deadline : September 16, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law, Wednesday, August 3, 2022, Press release picture

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

Topic:
Lawsuits
Back to newsroom
Back to Newsroom